title: Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia.
abstract: OBJECTIVE
  More than 95% of children with B-lineage acute lymphoblastic leukemia (ALL) achieve a clinical remission after the induction phase of chemotherapy (first 28 days) as evaluated by morphologic criteria. However, relapse occurs in approximately 30% of these children. The objective of this study was to determine whether the outcome of patients in clinical remission at the end of induction therapy could be predicted using a highly sensitive method to detect residual disease.
  
  
  METHODS
  All children diagnosed with B-lineage ALL at the Children's Hospital of Philadelphia during a 2-year period were eligible. The extent of residual leukemia was quantitated in remission marrow samples obtained at the end of induction therapy in 44 children using a phage clonogenic assay in association with complementarity-determining-region 3 (CDR3)-polymerase chain reaction (PCR).
  
  
  RESULTS
  Residual disease was a significant predictor of outcome independent of WBC count, age, or sex. The estimated relapse-free survival (RFS) during therapy was 50.4% (+/- 12.6%) for patients with high residual disease (> or = 0.6% leukemia cells among total marrow B cells) versus 91.9% (+/- 5.5%) for those with lower levels (P < .002). There were no significant differences in off-treatment RFS between patients with high or low residual disease who completed therapy in continuous remission (P = .82). The overall estimated RFS was 32.3% (+/- 11.6%) for patients with high residual disease versus 62.6% (+/- 10.7%) for patients with lower levels of residual leukemia cells, with a median follow-up of 5.3 years for patients in continuous remission (P < .008).
  
  
  CONCLUSIONS
  PCR detection of high residual disease at the end of induction therapy identifies patients at increased risk for relapse during therapy.
authors.affiliation: Division of Oncology, Children's Hospital of Philadelphia, PA.
authors.forename: R
authors.initials: R
authors.lastname: Wasserman
authors.forename: N
authors.initials: N
authors.lastname: Galili
authors.forename: Y
authors.initials: Y
authors.lastname: Ito
authors.forename: J H
authors.initials: JH
authors.lastname: Silber
authors.forename: B A
authors.initials: BA
authors.lastname: Reichard
authors.forename: S
authors.initials: S
authors.lastname: Shane
authors.forename: R B
authors.initials: RB
authors.lastname: Womer
authors.forename: B
authors.initials: B
authors.lastname: Lange
authors.forename: G
authors.initials: G
authors.lastname: Rovera
mesh_terms: D000293:Adolescent; D002051:Burkitt Lymphoma / Q000473:pathology* / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology* / Q000628:therapy*; D011237:Predictive Value of Tests; D012008:Recurrence; D012044:Regression Analysis; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome